Abstract
We have carried out an analysis of 44 patients undergoing allogeneic PBSC transplants from fully HLA-matched related donors with particular emphasis on engraftment kinetics and the incidence and severity of GVHD. The recipients had a median age of 37 years (range 5–56 years), 16 patients had standard-risk disease and 28 had poor-risk disease. GVHD prophylaxis was with cyclosporin A and methotrexate (n = 41), cyclosporin A alone (n = 2) or cyclosporin A and methylprednisolone (n = 1). Stem cells were mobilised using G-CSF, collecting a median of 5.75 × 106 CD34+ cells/kg recipient weight (range 0.94–35 × 106 CD34+ cells/kg). Engraftment times to a neutrophil count >0.5 × 109/l and platelets >20 × 109/l were achieved at a median of day +14 (range 10–25) and day + 14 (range 9–130) respectively. Patients receiving ⩾4 × 106 CD34+ cells/kg had significantly accelerated neutrophil and platelet engraftment and this number of CD34+ cells would appear to be a prerequisite for maximum engraftment using PBSC. Acute GVHD occurred in 25 of 43 evaluable patients although in only 12 was this clinically significant (grades II–IV). Chronic GVHD has occurred in 17 out of 36 evaluable patients, there was no significant difference between the standard- and poor-risk groups in incidence of either acute or chronic GVHD. In conclusion, these results confirm the feasibility of using PBSC for allogeneic transplantation without evidence for increased risk of either acute or chronic GVHD and provide further evidence supporting the potential of PBSC to replace bone marrow as the major source of haemopoietic cells for allogeneic transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miflin, G., Russell, N., Hutchinson, R. et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies – an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant 19, 9–13 (1997). https://doi.org/10.1038/sj.bmt.1700603
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700603
Keywords
This article is cited by
-
Slow platelet recovery after PBPC transplantation from unrelated donors
Bone Marrow Transplantation (2009)
-
The impact of post-thaw colony-forming units-granulocyte/macrophage on engraftment following unrelated cord blood transplantation in pediatric recipients
Bone Marrow Transplantation (2007)
-
Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation
Bone Marrow Transplantation (2005)
-
Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation
Leukemia (2003)
-
Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints
Bone Marrow Transplantation (2002)